Back to today’s briefing

Story perspectives

Salarius and Decoy Merge to Develop Cancer Therapies

1/14/2025

45 10

Summary

Story summary

Salarius Pharmaceuticals and Decoy Therapeutics are joining forces in an exciting merger to form a new powerhouse dedicated to developing peptide conjugate therapies targeting respiratory viruses and cancer. With a robust $7 million funding boost, this collaboration aims to fast-track clinical advancements, harnessing Decoy’s innovative IMP3ACT platform under the leadership of its experienced executive team.

1 of 1

Story summary

Salarius Pharmaceuticals and Decoy Therapeutics are joining forces in an exciting merger to form a new powerhouse dedicated to developing peptide conjugate therapies targeting respiratory viruses and cancer. With a robust $7 million funding boost, this collaboration aims to fast-track clinical advancements, harnessing Decoy’s innovative IMP3ACT platform under the leadership of its experienced executive team.